No studies have yet explored associations between plasma MCP-1 levels, angiogenesis, and the main clinical features in newly diagnosed, untreated myeloma patients, such as anemia, renal dysfunction, and bone disease, which was the aim of the present pilot study. This evidence concerns the gene CCL2 and Abnormal renal physiology.